1 Day
Source:
وكالة صدى نيوز
Postpartum medication lowers breast cancer risk
An international study indicates that the drug "Cabergoline," used to inhibit breast milk production after pregnancy loss or when breastfeeding is not possible, may reduce the risk of breast cancer by up to approximately 70% postpartum. Researchers found that women who took the medication during the weaning period were less likely to develop the disease, especially among women with genetic predispositions such as mutations in the "BRCA1" and "TP53" genes. The study, published in the journal "Cancer Discovery," analyzed records of over 150,000 women in Spain and Norway. It demonstrates that the drug helps facilitate the natural regression of breast tissue after weaning, reduces potential cancerous cells, and enhances local immunity. The researchers emphasize the need for clinical trials to confirm the effectiveness of "Cabergoline" as a preventive treatment against breast cancer, noting that current results do not yet support official approval of the drug for this purpose.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)